BERLIN (Reuters) - Baxter plans to start production of the COVID-19 vaccine by BioNTech and Pfizer in Germany in late February or early March, Juergen Fleischer, personnel chief at Baxter Germany, said.
“We are still in the process of converting the production facility for the demands of BioNTech’s deep-frozen product,” he said.
The company will also make vaccines for Novavax at the site, Baxter had announced on Monday.
Reporting by Andreas Rinke; Writing by Maria Sheahan, editing by Kirsti Knolle
Our Standards: The Thomson Reuters Trust Principles.